{"ticker": {"uuid": "cc80f937-724a-42d1-a52d-0ddff4bf3d31", "symbol": "INKT", "name": "Mink Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why You Should Add INKT Stock to Your Portfolio Now", "summary": "MiNK Therapeutics (INKT) is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for various life-threatening diseases, including oncology and respiratory conditions. The company's lead candidate, agenT-797, is showing promisin", "url": "https://www.tradingview.com/news/zacks:46ca6172a094b:0-here-s-why-you-should-add-inkt-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-07-16T16:41:53", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE5QWFpzVUJmVDdPa3ZRbkQ3Y09TMkJPYjZYVW1MajFSV3pUVWdCYU5fU3RlalBMM2ZqRWtrWVhkb3BWUDlRaXFibDlub1ZMT2xmNWV6S3hDZG5IOGxtaTlocWkydnlGNml6TlFv?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (INKT) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Mink Therapeutics Inc. (NASDAQ: INKT) with a focus on its price action for tactical trading, identifying weak sentiment across all horizons and supporting a short bias. It details an exceptional risk-reward setup targeting a 54.4% gain versus 0.3% risk, and ", "url": "https://news.stocktradersdaily.com/news_release/52/Why_INKT_Price_Action_Is_Critical_for_Tactical_Trading_071326114002_1784000402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T23:40:00", "published_display": "13 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mink Therapeutics (INKT) Proxy filing Summary", "summary": "Mink Therapeutics (INKT) has released a proxy filing summary ahead of its Annual Meeting on June 17, 2026. The meeting will address the election of three Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm. Stockholders as of A", "url": "https://quartr.com/events/mink-therapeutics-inkt-proxy-filing_onWxlczU", "source_name": "Quartr", "published_at": "2026-07-10T23:09:35", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary", "summary": "Mink Therapeutics presented a summary of their pipeline and development status at the H.C. Wainwright 26th Annual Global Investment Conference 2024. The company focuses on off-the-shelf invariant natural killer T (iNKT) cell therapies, with their lead program agenT-797 in Phase I", "url": "https://quartr.com/events/mink-therapeutics-inkt-h-c-wainwright-26th-annual-global-investment-conference-2024_onWxin8K", "source_name": "Quartr", "published_at": "2026-07-10T19:09:35", "published_display": "10 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) Q1 2025 earnings summary", "summary": "Mink Therapeutics (INKT) announced Q1 2025 financial results, reporting a net loss of $2.8 million and a cash balance of $3.2 million. The company achieved significant clinical milestones in cancer therapy and secured probable NIAID funding for its GVHD program, expecting to pres", "url": "https://quartr.com/events/mink-therapeutics-inc-inkt-q1-2025_onWxQpNO", "source_name": "Quartr", "published_at": "2026-07-09T04:40:47", "published_display": "09 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cost of goods sold of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article focuses on the \"Cost of goods sold\" for MiNK Therapeutics, Inc., specifically for its listing on the Dusseldorf Stock Exchange under the ticker 6Q40. The content is presented as a financial data point within the broader context of the company's financial overview on ", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-income-statement/cost-of-goods/", "source_name": "TradingView", "published_at": "2026-07-08T05:39:34", "published_display": "08 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (INKT)", "summary": "This article provides an in-depth analysis of Mink Therapeutics Inc. (NASDAQ: INKT) utilizing AI models to identify momentum shifts and suggest trading strategies. It highlights a near-term weak sentiment that may lead to a resumption of long-term weakness after a neutral shift, ", "url": "https://news.stocktradersdaily.com/news_release/81/Understanding_Momentum_Shifts_in_INKT_070226103202_1783045922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T22:32:00", "published_display": "02 Jul 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM:INKT) has been added to the Russell Microcap Value Benchmark Index, as reported on June 29, 2026. This inclusion signifies the company's recognition within the microcap investment community. The clinical-stage biopharmaceutical company focuses on", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:32:47", "published_display": "29 Jun 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Benchmark", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Value Benchmark Index. This inclusion highlights the company's growing presence in the financial markets and follows several other recent inclusions in various Russell Microcap and 3000E indices. MiNK Th", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-3000e-value-benchmark-ce7f5fddd988f126", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:40:43", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell Microcap Growth Benchmark Index. This inclusion means the company's stock will now be tracked by this widely recognized index, potentially increasing its visibility and attractiveness to growth-focused investo", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bf723", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:28:37", "published_display": "29 Jun 2026 12:28", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSjNXOVNFOEFKQzBscVdKUzYxcnhPcHRfT1JZREdBY01wNkZHR0s5UzNYVHZZNncwZlJEbGN1VWcwSEtMWmpuUEdSN2V0MVRvdEZjeVA5ZUM3VmhJdEpWaTl4ekpOVFVDdUdIVXFJUnp4UVBTVi13QjJmd1NwRkcxYU1UakNqWWdsSGR4Y3lrZlpyc0tGRzZGeWdxRXppRTRMTXc2Wm5hSzZBM092S3htYXZ4RHQyS2VWQlR4NA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT), a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, has been added to the Russell Microcap Index. This inclusion follows several recent developments for the company, including", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-index-ce7f5fdedd88f622", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:41:37", "published_display": "29 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Growth Benchmark", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Growth Benchmark. This inclusion follows previous additions to the Russell Microcap Value and Microcap Growth Benchmark Indexes. MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bf525", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:46:00", "published_display": "29 Jun 2026 04:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INKT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MiNK Therapeutics, Inc. (INKT) stock, including analyst price targets and a prediction for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T07:41:15", "published_display": "28 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. \u2013 NASDAQ:INKT", "summary": "The article provides financial data for MiNK Therapeutics, Inc. (NASDAQ: INKT), focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time of publication, with no trades observed.", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:15", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT)", "summary": "This article provides an overview of MiNK Therapeutics, Inc. (NASDAQ:INKT) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings date, and past earnings and revenue f", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:15", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MiNK Therapeutics, Inc. \u2013 NASDAQ:INKT", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for MiNK Therapeutics, Inc. (NASDAQ: INKT). It provides a snapshot of this financial data on the TradingView platform, noting that the market was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:57", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics (Nasdaq:INKT) - Stock Analysis", "summary": "MiNK Therapeutics (Nasdaq:INKT) is a clinical-stage biopharmaceutical company focused on allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases. The company is currently trading significantly below its estimated fair value and faces risks including ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inkt/mink-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-24T23:10:15", "published_display": "24 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Mink Therapeutics Inc For: 23 June By Investing.com", "summary": "This article reports that Mink Therapeutics Inc. filed a Form 8K on June 23, 2026. This filing is a standard requirement for significant events that shareholders should be aware of. The article also provides current market data for various indices, commodities, bonds, and shares,", "url": "https://ng.investing.com/news/stock-market-news/form-8k-mink-therapeutics-inc-for-23-june-93CH-2570392", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T10:41:11", "published_display": "24 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article provides financial data on total liabilities and shareholders' equities for MiNK Therapeutics, Inc. (DUS:6Q40) as listed on the Dusseldorf Stock Exchange. It highlights the availability of this specific financial metric from TradingView, which sources its data from I", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-balance-sheet/total-liabilities-shrhldrs-equity/", "source_name": "TradingView", "published_at": "2026-06-23T19:10:22", "published_display": "23 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting", "summary": "MiNK Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, where investors reelected Garo Armen, Barbara Ryan, and John Holcomb as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of KPMG LLP as the independent re", "url": "https://www.stocktitan.net/sec-filings/INKT/8-k-mi-nk-therapeutics-inc-reports-material-event-b16531881164.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:10:22", "published_display": "23 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) AGM 2026 Summary", "summary": "The Mink Therapeutics (INKT) Annual General Meeting (AGM) 2026 summary details the formal proceedings, including the appointment of an Inspector of Elections and the establishment of a quorum. Key voting outcomes included the approval of three Class II directors for three-year te", "url": "https://quartr.com/events/mink-therapeutics-inkt-agm-2026_onWxljHR", "source_name": "Quartr", "published_at": "2026-06-22T21:11:15", "published_display": "22 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (INKT) Movement", "summary": "The article analyzes Mink Therapeutics Inc. (NASDAQ: INKT), highlighting mixed sentiment leading to choppy conditions. It reveals an exceptional 295.0:1 risk-reward setup, targeting a 93.5% gain, and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging)", "url": "https://news.stocktradersdaily.com/news_release/89/Avoiding_Lag:_Real-Time_Signals_in_INKT_Movement_062126092002_1782091202.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T21:20:00", "published_display": "21 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventory turnover of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "The article discusses the inventory turnover of MiNK Therapeutics, Inc. (DUS: 6Q40) on the Dusseldorf Stock Exchange. It provides general financial information about the company's stock activity, noting that the market is currently closed with no trades. The content primarily foc", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-statistics-and-ratios/invent-turnover/", "source_name": "TradingView", "published_at": "2026-06-21T16:10:10", "published_display": "21 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Book value per share of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article provides financial information for MiNK Therapeutics, Inc. (DUS:6Q40), specifically focusing on its book value per share. The content is presented within the TradingView platform, noting that the market is currently closed for this stock.", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-statistics-and-ratios/book-value-per-share/", "source_name": "TradingView", "published_at": "2026-06-19T15:11:17", "published_display": "19 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc. Cash Flow \u2013 DUS:6Q40", "summary": "This article provides key cash flow figures for MiNK Therapeutics, Inc. (DUS:6Q40). It highlights that the free cash flow for Q1 2026 was -1.50M EUR, and for the full year 2025, operating cash flow and free cash flow were both -5.04M EUR. The article also presents a historical br", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-19T09:39:28", "published_display": "19 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Mink Therapeutics Inc (INKT), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation dimensions have not yet been disclosed by the company. The page also presents current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inkt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:18", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Inc (INKT) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9JRG1nOXF2UGh6Y1JLSmowMV81UGU1aDd2SkYydUVPbDd6MXdQdUZ1SkFqWjNUSWhQQmN4aHlHUG5vR0tnZzdJQ1BHXzNNRjlxVlFvbWRadHdvM1VSbGZzV3JTS3RCeGhmYXNsQTVLNDQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:56:06+00:00", "published_display": "17 Jun 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics director Barbara Ryan sells $19,141 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQd01RNHI0S0FOV0otR1kxbTZON0ZjbTVFakc4bm1Bc0J6UXlyYjJVVndxOFFjWWtVVUdCMGV6QVJ6TGMtZXpoZkhrLUVjVGUzbTBvTXhORXFWQ0NVdEp0X2V6WEhWSXE5eHhCeGFoNnVSc012UUxGcXd6aTBEWWtoSHlDbzhEa2xoSzFKWmx3SURBTkZYOUphU1BDRkVRSmhzazRLRm40d2dCMmpXWXVWVTZBTGpUaUllZ1M4MEZXUU1UaFk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-announces-virtual-2026-203000647.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T20:30:00+00:00", "published_display": "03 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-announces-first-patient-130400018.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T13:04:00+00:00", "published_display": "28 May 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdl9QNHJCUjU1Ujg5QXBBOGliQXJ2NHRsdkxlQzFVOEl3Q2N2NHpKamN3YTBVVldvY3E3bjhENkxwVG5VSzlDMlZOS2R5TjJLVGxnY2NxRW5heERsSFQ2U0paMW5VRlZIN2xiaG9sT3drLVpjREd0QVJjMklMVV8tT20xVVdkZmFMTm5Help0V09RRmRDYVVFdXU3eGtJRV9FRFU5UUZ2RTQ5TlI2dzM1UmVjRjhvRzI0YWJJeUpPZEVxRWVXMVRuWmpQNWdPVkNpTV9RdWtQSHhvTFFTbWstc2NDYTBrVDQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Mink Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMUFkMF9rWmQ0enZDUzFqd3RDVWhaZHpUelhBOGFBVzl3TW14cmc2VU9kX0ExY0g1OHFBNk9vRHI1WWJKeXNsdFA0YXBNbnNSNXJ5c2lSZ093MUQydmNNTzVfcWx6MmJMeHlTN2dMQVFnT1VNUzBtM1Vud1lseDFoMHVOeGlfQ3VfcTRTNGFyV0hoTjBaRjJCU3M2THUwc0xEX1lWeWN4anJDUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-reports-data-agent-150700113.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T15:07:00+00:00", "published_display": "20 May 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNUWxJNFFtODE2cnVvMi1ZNjEtMTJhaVZydlJfV0d3TGlqeEhEcTJoUXVRX0hqLXlXb1hhLWpaMElqQjRfMk8zMW5JN3dwSzZhVW5TQjhhSlhFNFl6V3lIc01zc0JGSDlEY212bDM5UUhscWhUSDIwdU96bXk4SzdNVVNDT1hFcHVUZTdwRDFJdUNyNHhzeHc?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-inc-inkt-q1-230144600.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T23:01:44+00:00", "published_display": "15 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/815af32e-589d-3963-a252-5b298abda693/mink-therapeutics-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-15T14:12:26+00:00", "published_display": "15 May 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-reports-first-quarter-113000079.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdmhwNjhXMnRxVUxpbTMyYkxuQk9jWGVfU0ZrTUtGTmIzVjRIRjZac0hvMkE2X1I3OWlrY1NlNng3aFRfT3dUbTYzclZTLUo1aUJseDZwRW82XzZqQXB0Q2QtQkNiMm4zeWhSenVLM0JkaGVRWUYtaHBBMmFLNExUQXFDN2lsNUJzTDBzZnhhVFlnbjJsaTlNZ1FvWEQ2ZnNoSFRmal9qek1FQUdzRjZIWjAxZ2ZzNkNtUXJqUFVXSm1RblV2WHpkN3IwYw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MINK THERAPEUTICS ($INKT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNcnNHQzJhd3hPMmdxU1JndHZ6ZkxzRDNURF9YUXpOcjdUclpwMVVKN19jUUd2REtOYWRadkZPZ1NabS1iR1VuZlk0ZHNGYm92S1k1T201M2N2NFh6MUxXLXZYWXlGd1hmWDJwaENIbThXSzNLQVpISG9POXhGRkhkWU5XaV9DWjBNX0NWYzRVZEJVUFdr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-first-lviv-territorial-113000184.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOekZJWnR1enRHd2hmVGI0R0Fjc1lFWEF4bXZuRktwQUlZV2t1ODdCb19ic2ZlQ2lmZ0dCV2dBeFJJXzE1UWZ0RmNaM0dlRkhuaGNKZnV1akQxZHpfT25EdFpJTGs4YTFPTHp5NUU4WkVWdkdnbF9nUUdFWGNUY1F2V3RXOFJ1Mkc0bjdBQUdZV2JkeVJFekRNek40dFpJdlk?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MiNK Therapeutics stock soars 80% on C-Further collaboration By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcTZOMWJpVV9rVmF2WWVrVEJIVmNtYzRDUXFpMlFDU2hDalhaXy1ibHZwdWU1cXBsUjhaelQyeVFWMm1vcVA4QmIxeEdZNWpvNWp4NE5rRzh2NERTTnhNUG1Sd2xUcW1NdERfTjFid0JGQ0pjWmZGeGRJSW9FdGZ5clFkRG56MGg4bk9ka2JoXzBtUTZjZlBwOEUyV3RNNUlwUm9mRHR4QU1fNU10WkxaTzMxVy1ZVXdyWFFB?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-03-10T11:15:38+00:00", "published_display": "10 Mar 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Stock Gains Amid New Market Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5FSXVheGE5bjhGV0h5UDVXUFZIQWU0ZlMydF9lU09saUJRVFp4Z0V3OTlkdTBRSUxCbVZVSGloY1Zac3RKV2JIaUxDVUhHQ3RCU3FRSldBOVkxNlBSR0tIRlQ3YW1oeUpGcWlfdTVGM2FRaGUxZ2FDWlh3ZU9ZcDg?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQX3EyWTV6SkthWU1oQlFNNU5DdVdsRzdEcTJaQTZlY0JzQUxzMjZRclVqUml0Uk1aYlo5bkk3d1V5X2I1TGtlaTlhdEZsdHl2eWVFb2tJWnFodFVZczRONkN0emZiN3g1QVVIVDBlR1F1aC1aS2hXU0VhelNJSGdKZmJndFNtNmhlX1E?oc=5", "source_name": "Tokenist", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNN2JCVUFzSEhSeTM5clpQdUxWam02RVBqM1RBdHdBV1VuZ21ENjlKamdfZEFFRVlVMGMzVnJPYzdzajFjUXJwQjQwTEtSWHZNRnU1VXpTeGczcXpWaFNrSTFiWElOSEJHbE1YZGNaYXN5V1VOWS1ETEhlUVR0am9Held1SzFBQkZ4a25tWm16bXNEMEctRi1GR0V6bHpxWjZHcTA0cjJnYUNhVnBmejVmTGsyWXRnRmtYWXdjMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxPZm56WXVCemE2MG9xYW84allaUlh3ZlVQaFpYR042X0ZFWFc3SzlOUkt1bG5KaDdLRFhjZ29WOHJzUF9kcTloM2NIUmlNUThMX2NWTGtDTWtNc0J1N19mSkxwVzVpcS1kczFodDVqMTZTYUpWRjF1M05CNTc5aTc0c3Yxb0tSNTUxcmUzOU1MX05qV2tFb2NlbkswZzl0bGs2M0tvTDEwczU5dHg0Wll1dXc0am1JUDNNNl8tT0g3bExodkVsd2NYWkctdkZIU2VJdnpKMjBkQnZ0NGxqczJUcTZNaWRlZG1rWm9UV3lXSy12WDE1d0JvX3hfT3FNR0o1VUp5MzBVTHRZS0o0MjBHNVhLZUxHV05BZWc?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy MiNK Therapeutics, Inc. (INKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE85dkN1WUU2aEZoUWE5VU1obk1wbGZyc01VcFU0TUdjNXI5OXRFaVY3cERTXzJtQVdpU1RoR3lfdFM0dDh1TUpoM3l5OFpvMWZqdXB6MkxEa29LUDFGdUc5U1k3UTBESG5NRkY0Vg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-22T07:00:00+00:00", "published_display": "22 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1CY0xEXzdNY2dCTlA3OU8zU2RuQXhfYmNkUng3b1FxN2xheTZaTmFKazZrWFE5TXp6ZXBNV2NaenVjTmpOdW9BVlU1Mm5DMXFONXNMSzZ0Sk5ZaVg2NDlfWFQ4ckgxQ1dUTzZIOENXdW4yT2RGa0tF?oc=5", "source_name": "Oncodaily", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNeUlja3dvM1IxZHZPSjlrVjh5MDRueGg0V2tlTDV4cHBrdGVkcGRaOGlnUkMzM2xlZkJRWlp2SzRjZ1QzbFhuVGl2Rl9QZDZQbDh1cWljU21OSmJ6VlF5U0RlekRXZnlOdjRhQlRqeTNKalFVaTdLdDF1c3lJRFVSWU5QcXFPMDdYay1TblZ2ZWJNRU03cnFFT2ZPVTVuRFlUdzR6ZjRyZXBXRzdaRkw5dFZpemFuSHVuNHFrRDdVVGxVWGNOakNtR0tqWW9VRG5oNi15eV8wTHBPaF9LQXZZOHJOLVXSAeoBQVVfeXFMTTNlTUdCR0xpZjFXZEhpVG9PeVByYjZaTWpWZlI5U2J3aG1lSUxyMTBTZlFvTUxLaGZ5cFpLWGVIOTZLUFFxMmJVT3RPTWpFMDVwNHNlNURldEkwZmtQSkZ0ZUdLVVhBOC1Zd2piN3ZZblBaWF9xRDRTaG5qR3lWeTFWU0xJNkYwaDE1VjAzUXF5QUk1QWQzX21WdFRKaVR5eGxnaFBxZk1fbUlaazFEZkwxZnR2dEk2aUJzcmZ2RkVWbmRBcEJRcmZBdy1BazNHY0hoU1BQTGZ3QjFJdGNvOVBaS3NzNjU0TlF3?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-13T07:00:00+00:00", "published_display": "13 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Here's Why You Should Add INKT Stock to Your Portfolio Now", "summary": "MiNK Therapeutics (INKT) is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for various life-threatening diseases, including oncology and respiratory conditions. The company's lead candidate, agenT-797, is showing promisin", "url": "https://www.tradingview.com/news/zacks:46ca6172a094b:0-here-s-why-you-should-add-inkt-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-07-16T16:41:53", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE5QWFpzVUJmVDdPa3ZRbkQ3Y09TMkJPYjZYVW1MajFSV3pUVWdCYU5fU3RlalBMM2ZqRWtrWVhkb3BWUDlRaXFibDlub1ZMT2xmNWV6S3hDZG5IOGxtaTlocWkydnlGNml6TlFv?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (INKT) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Mink Therapeutics Inc. (NASDAQ: INKT) with a focus on its price action for tactical trading, identifying weak sentiment across all horizons and supporting a short bias. It details an exceptional risk-reward setup targeting a 54.4% gain versus 0.3% risk, and ", "url": "https://news.stocktradersdaily.com/news_release/52/Why_INKT_Price_Action_Is_Critical_for_Tactical_Trading_071326114002_1784000402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T23:40:00", "published_display": "13 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) Proxy filing Summary", "summary": "Mink Therapeutics (INKT) has released a proxy filing summary ahead of its Annual Meeting on June 17, 2026. The meeting will address the election of three Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm. Stockholders as of A", "url": "https://quartr.com/events/mink-therapeutics-inkt-proxy-filing_onWxlczU", "source_name": "Quartr", "published_at": "2026-07-10T23:09:35", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary", "summary": "Mink Therapeutics presented a summary of their pipeline and development status at the H.C. Wainwright 26th Annual Global Investment Conference 2024. The company focuses on off-the-shelf invariant natural killer T (iNKT) cell therapies, with their lead program agenT-797 in Phase I", "url": "https://quartr.com/events/mink-therapeutics-inkt-h-c-wainwright-26th-annual-global-investment-conference-2024_onWxin8K", "source_name": "Quartr", "published_at": "2026-07-10T19:09:35", "published_display": "10 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) Q1 2025 earnings summary", "summary": "Mink Therapeutics (INKT) announced Q1 2025 financial results, reporting a net loss of $2.8 million and a cash balance of $3.2 million. The company achieved significant clinical milestones in cancer therapy and secured probable NIAID funding for its GVHD program, expecting to pres", "url": "https://quartr.com/events/mink-therapeutics-inc-inkt-q1-2025_onWxQpNO", "source_name": "Quartr", "published_at": "2026-07-09T04:40:47", "published_display": "09 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cost of goods sold of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article focuses on the \"Cost of goods sold\" for MiNK Therapeutics, Inc., specifically for its listing on the Dusseldorf Stock Exchange under the ticker 6Q40. The content is presented as a financial data point within the broader context of the company's financial overview on ", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-income-statement/cost-of-goods/", "source_name": "TradingView", "published_at": "2026-07-08T05:39:34", "published_display": "08 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (INKT)", "summary": "This article provides an in-depth analysis of Mink Therapeutics Inc. (NASDAQ: INKT) utilizing AI models to identify momentum shifts and suggest trading strategies. It highlights a near-term weak sentiment that may lead to a resumption of long-term weakness after a neutral shift, ", "url": "https://news.stocktradersdaily.com/news_release/81/Understanding_Momentum_Shifts_in_INKT_070226103202_1783045922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T22:32:00", "published_display": "02 Jul 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM:INKT) has been added to the Russell Microcap Value Benchmark Index, as reported on June 29, 2026. This inclusion signifies the company's recognition within the microcap investment community. The clinical-stage biopharmaceutical company focuses on", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:32:47", "published_display": "29 Jun 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Benchmark", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Value Benchmark Index. This inclusion highlights the company's growing presence in the financial markets and follows several other recent inclusions in various Russell Microcap and 3000E indices. MiNK Th", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-3000e-value-benchmark-ce7f5fddd988f126", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:40:43", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell Microcap Growth Benchmark Index. This inclusion means the company's stock will now be tracked by this widely recognized index, potentially increasing its visibility and attractiveness to growth-focused investo", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bf723", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:28:37", "published_display": "29 Jun 2026 12:28", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSjNXOVNFOEFKQzBscVdKUzYxcnhPcHRfT1JZREdBY01wNkZHR0s5UzNYVHZZNncwZlJEbGN1VWcwSEtMWmpuUEdSN2V0MVRvdEZjeVA5ZUM3VmhJdEpWaTl4ekpOVFVDdUdIVXFJUnp4UVBTVi13QjJmd1NwRkcxYU1UakNqWWdsSGR4Y3lrZlpyc0tGRzZGeWdxRXppRTRMTXc2Wm5hSzZBM092S3htYXZ4RHQyS2VWQlR4NA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Index", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT), a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, has been added to the Russell Microcap Index. This inclusion follows several recent developments for the company, including", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-microcap-index-ce7f5fdedd88f622", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:41:37", "published_display": "29 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Growth Benchmark", "summary": "MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Growth Benchmark. This inclusion follows previous additions to the Russell Microcap Value and Microcap Growth Benchmark Indexes. MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on", "url": "https://www.marketscreener.com/news/mink-therapeutics-inc-nasdaqcm-inkt-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bf525", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:46:00", "published_display": "29 Jun 2026 04:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INKT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MiNK Therapeutics, Inc. (INKT) stock, including analyst price targets and a prediction for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T07:41:15", "published_display": "28 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. \u2013 NASDAQ:INKT", "summary": "The article provides financial data for MiNK Therapeutics, Inc. (NASDAQ: INKT), focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time of publication, with no trades observed.", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:15", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT)", "summary": "This article provides an overview of MiNK Therapeutics, Inc. (NASDAQ:INKT) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings date, and past earnings and revenue f", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:15", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MiNK Therapeutics, Inc. \u2013 NASDAQ:INKT", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for MiNK Therapeutics, Inc. (NASDAQ: INKT). It provides a snapshot of this financial data on the TradingView platform, noting that the market was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/NASDAQ-INKT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:57", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics (Nasdaq:INKT) - Stock Analysis", "summary": "MiNK Therapeutics (Nasdaq:INKT) is a clinical-stage biopharmaceutical company focused on allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases. The company is currently trading significantly below its estimated fair value and faces risks including ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inkt/mink-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-24T23:10:15", "published_display": "24 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Mink Therapeutics Inc For: 23 June By Investing.com", "summary": "This article reports that Mink Therapeutics Inc. filed a Form 8K on June 23, 2026. This filing is a standard requirement for significant events that shareholders should be aware of. The article also provides current market data for various indices, commodities, bonds, and shares,", "url": "https://ng.investing.com/news/stock-market-news/form-8k-mink-therapeutics-inc-for-23-june-93CH-2570392", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T10:41:11", "published_display": "24 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article provides financial data on total liabilities and shareholders' equities for MiNK Therapeutics, Inc. (DUS:6Q40) as listed on the Dusseldorf Stock Exchange. It highlights the availability of this specific financial metric from TradingView, which sources its data from I", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-balance-sheet/total-liabilities-shrhldrs-equity/", "source_name": "TradingView", "published_at": "2026-06-23T19:10:22", "published_display": "23 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting", "summary": "MiNK Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, where investors reelected Garo Armen, Barbara Ryan, and John Holcomb as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of KPMG LLP as the independent re", "url": "https://www.stocktitan.net/sec-filings/INKT/8-k-mi-nk-therapeutics-inc-reports-material-event-b16531881164.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:10:22", "published_display": "23 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics (INKT) AGM 2026 Summary", "summary": "The Mink Therapeutics (INKT) Annual General Meeting (AGM) 2026 summary details the formal proceedings, including the appointment of an Inspector of Elections and the establishment of a quorum. Key voting outcomes included the approval of three Class II directors for three-year te", "url": "https://quartr.com/events/mink-therapeutics-inkt-agm-2026_onWxljHR", "source_name": "Quartr", "published_at": "2026-06-22T21:11:15", "published_display": "22 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (INKT) Movement", "summary": "The article analyzes Mink Therapeutics Inc. (NASDAQ: INKT), highlighting mixed sentiment leading to choppy conditions. It reveals an exceptional 295.0:1 risk-reward setup, targeting a 93.5% gain, and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging)", "url": "https://news.stocktradersdaily.com/news_release/89/Avoiding_Lag:_Real-Time_Signals_in_INKT_Movement_062126092002_1782091202.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T21:20:00", "published_display": "21 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inventory turnover of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "The article discusses the inventory turnover of MiNK Therapeutics, Inc. (DUS: 6Q40) on the Dusseldorf Stock Exchange. It provides general financial information about the company's stock activity, noting that the market is currently closed with no trades. The content primarily foc", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-statistics-and-ratios/invent-turnover/", "source_name": "TradingView", "published_at": "2026-06-21T16:10:10", "published_display": "21 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Book value per share of MiNK Therapeutics, Inc. \u2013 DUS:6Q40", "summary": "This article provides financial information for MiNK Therapeutics, Inc. (DUS:6Q40), specifically focusing on its book value per share. The content is presented within the TradingView platform, noting that the market is currently closed for this stock.", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-statistics-and-ratios/book-value-per-share/", "source_name": "TradingView", "published_at": "2026-06-19T15:11:17", "published_display": "19 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc. Cash Flow \u2013 DUS:6Q40", "summary": "This article provides key cash flow figures for MiNK Therapeutics, Inc. (DUS:6Q40). It highlights that the free cash flow for Q1 2026 was -1.50M EUR, and for the full year 2025, operating cash flow and free cash flow were both -5.04M EUR. The article also presents a historical br", "url": "https://www.tradingview.com/symbols/DUS-6Q40/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-19T09:39:28", "published_display": "19 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Mink Therapeutics Inc (INKT), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation dimensions have not yet been disclosed by the company. The page also presents current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inkt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:18", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Inc (INKT) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9JRG1nOXF2UGh6Y1JLSmowMV81UGU1aDd2SkYydUVPbDd6MXdQdUZ1SkFqWjNUSWhQQmN4aHlHUG5vR0tnZzdJQ1BHXzNNRjlxVlFvbWRadHdvM1VSbGZzV3JTS3RCeGhmYXNsQTVLNDQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:56:06+00:00", "published_display": "17 Jun 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics director Barbara Ryan sells $19,141 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQd01RNHI0S0FOV0otR1kxbTZON0ZjbTVFakc4bm1Bc0J6UXlyYjJVVndxOFFjWWtVVUdCMGV6QVJ6TGMtZXpoZkhrLUVjVGUzbTBvTXhORXFWQ0NVdEp0X2V6WEhWSXE5eHhCeGFoNnVSc012UUxGcXd6aTBEWWtoSHlDbzhEa2xoSzFKWmx3SURBTkZYOUphU1BDRkVRSmhzazRLRm40d2dCMmpXWXVWVTZBTGpUaUllZ1M4MEZXUU1UaFk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-announces-virtual-2026-203000647.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T20:30:00+00:00", "published_display": "03 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-announces-first-patient-130400018.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T13:04:00+00:00", "published_display": "28 May 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdl9QNHJCUjU1Ujg5QXBBOGliQXJ2NHRsdkxlQzFVOEl3Q2N2NHpKamN3YTBVVldvY3E3bjhENkxwVG5VSzlDMlZOS2R5TjJLVGxnY2NxRW5heERsSFQ2U0paMW5VRlZIN2xiaG9sT3drLVpjREd0QVJjMklMVV8tT20xVVdkZmFMTm5Help0V09RRmRDYVVFdXU3eGtJRV9FRFU5UUZ2RTQ5TlI2dzM1UmVjRjhvRzI0YWJJeUpPZEVxRWVXMVRuWmpQNWdPVkNpTV9RdWtQSHhvTFFTbWstc2NDYTBrVDQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Mink Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMUFkMF9rWmQ0enZDUzFqd3RDVWhaZHpUelhBOGFBVzl3TW14cmc2VU9kX0ExY0g1OHFBNk9vRHI1WWJKeXNsdFA0YXBNbnNSNXJ5c2lSZ093MUQydmNNTzVfcWx6MmJMeHlTN2dMQVFnT1VNUzBtM1Vud1lseDFoMHVOeGlfQ3VfcTRTNGFyV0hoTjBaRjJCU3M2THUwc0xEX1lWeWN4anJDUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-reports-data-agent-150700113.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T15:07:00+00:00", "published_display": "20 May 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNUWxJNFFtODE2cnVvMi1ZNjEtMTJhaVZydlJfV0d3TGlqeEhEcTJoUXVRX0hqLXlXb1hhLWpaMElqQjRfMk8zMW5JN3dwSzZhVW5TQjhhSlhFNFl6V3lIc01zc0JGSDlEY212bDM5UUhscWhUSDIwdU96bXk4SzdNVVNDT1hFcHVUZTdwRDFJdUNyNHhzeHc?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-inc-inkt-q1-230144600.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T23:01:44+00:00", "published_display": "15 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/815af32e-589d-3963-a252-5b298abda693/mink-therapeutics-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-15T14:12:26+00:00", "published_display": "15 May 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-reports-first-quarter-113000079.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdmhwNjhXMnRxVUxpbTMyYkxuQk9jWGVfU0ZrTUtGTmIzVjRIRjZac0hvMkE2X1I3OWlrY1NlNng3aFRfT3dUbTYzclZTLUo1aUJseDZwRW82XzZqQXB0Q2QtQkNiMm4zeWhSenVLM0JkaGVRWUYtaHBBMmFLNExUQXFDN2lsNUJzTDBzZnhhVFlnbjJsaTlNZ1FvWEQ2ZnNoSFRmal9qek1FQUdzRjZIWjAxZ2ZzNkNtUXJqUFVXSm1RblV2WHpkN3IwYw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MINK THERAPEUTICS ($INKT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNcnNHQzJhd3hPMmdxU1JndHZ6ZkxzRDNURF9YUXpOcjdUclpwMVVKN19jUUd2REtOYWRadkZPZ1NabS1iR1VuZlk0ZHNGYm92S1k1T201M2N2NFh6MUxXLXZYWXlGd1hmWDJwaENIbThXSzNLQVpISG9POXhGRkhkWU5XaV9DWjBNX0NWYzRVZEJVUFdr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mink-therapeutics-first-lviv-territorial-113000184.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOekZJWnR1enRHd2hmVGI0R0Fjc1lFWEF4bXZuRktwQUlZV2t1ODdCb19ic2ZlQ2lmZ0dCV2dBeFJJXzE1UWZ0RmNaM0dlRkhuaGNKZnV1akQxZHpfT25EdFpJTGs4YTFPTHp5NUU4WkVWdkdnbF9nUUdFWGNUY1F2V3RXOFJ1Mkc0bjdBQUdZV2JkeVJFekRNek40dFpJdlk?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics stock soars 80% on C-Further collaboration By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcTZOMWJpVV9rVmF2WWVrVEJIVmNtYzRDUXFpMlFDU2hDalhaXy1ibHZwdWU1cXBsUjhaelQyeVFWMm1vcVA4QmIxeEdZNWpvNWp4NE5rRzh2NERTTnhNUG1Sd2xUcW1NdERfTjFid0JGQ0pjWmZGeGRJSW9FdGZ5clFkRG56MGg4bk9ka2JoXzBtUTZjZlBwOEUyV3RNNUlwUm9mRHR4QU1fNU10WkxaTzMxVy1ZVXdyWFFB?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-03-10T11:15:38+00:00", "published_display": "10 Mar 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Stock Gains Amid New Market Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5FSXVheGE5bjhGV0h5UDVXUFZIQWU0ZlMydF9lU09saUJRVFp4Z0V3OTlkdTBRSUxCbVZVSGloY1Zac3RKV2JIaUxDVUhHQ3RCU3FRSldBOVkxNlBSR0tIRlQ3YW1oeUpGcWlfdTVGM2FRaGUxZ2FDWlh3ZU9ZcDg?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQX3EyWTV6SkthWU1oQlFNNU5DdVdsRzdEcTJaQTZlY0JzQUxzMjZRclVqUml0Uk1aYlo5bkk3d1V5X2I1TGtlaTlhdEZsdHl2eWVFb2tJWnFodFVZczRONkN0emZiN3g1QVVIVDBlR1F1aC1aS2hXU0VhelNJSGdKZmJndFNtNmhlX1E?oc=5", "source_name": "Tokenist", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNN2JCVUFzSEhSeTM5clpQdUxWam02RVBqM1RBdHdBV1VuZ21ENjlKamdfZEFFRVlVMGMzVnJPYzdzajFjUXJwQjQwTEtSWHZNRnU1VXpTeGczcXpWaFNrSTFiWElOSEJHbE1YZGNaYXN5V1VOWS1ETEhlUVR0am9Held1SzFBQkZ4a25tWm16bXNEMEctRi1GR0V6bHpxWjZHcTA0cjJnYUNhVnBmejVmTGsyWXRnRmtYWXdjMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxPZm56WXVCemE2MG9xYW84allaUlh3ZlVQaFpYR042X0ZFWFc3SzlOUkt1bG5KaDdLRFhjZ29WOHJzUF9kcTloM2NIUmlNUThMX2NWTGtDTWtNc0J1N19mSkxwVzVpcS1kczFodDVqMTZTYUpWRjF1M05CNTc5aTc0c3Yxb0tSNTUxcmUzOU1MX05qV2tFb2NlbkswZzl0bGs2M0tvTDEwczU5dHg0Wll1dXc0am1JUDNNNl8tT0g3bExodkVsd2NYWkctdkZIU2VJdnpKMjBkQnZ0NGxqczJUcTZNaWRlZG1rWm9UV3lXSy12WDE1d0JvX3hfT3FNR0o1VUp5MzBVTHRZS0o0MjBHNVhLZUxHV05BZWc?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy MiNK Therapeutics, Inc. (INKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE85dkN1WUU2aEZoUWE5VU1obk1wbGZyc01VcFU0TUdjNXI5OXRFaVY3cERTXzJtQVdpU1RoR3lfdFM0dDh1TUpoM3l5OFpvMWZqdXB6MkxEa29LUDFGdUc5U1k3UTBESG5NRkY0Vg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-22T07:00:00+00:00", "published_display": "22 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1CY0xEXzdNY2dCTlA3OU8zU2RuQXhfYmNkUng3b1FxN2xheTZaTmFKazZrWFE5TXp6ZXBNV2NaenVjTmpOdW9BVlU1Mm5DMXFONXNMSzZ0Sk5ZaVg2NDlfWFQ4ckgxQ1dUTzZIOENXdW4yT2RGa0tF?oc=5", "source_name": "Oncodaily", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-13T07:00:00+00:00", "published_display": "13 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 61, "sentiment_summary": {"positive": 12, "negative": 3, "neutral": 46, "score": 53, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 10.11, "count": 20}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 10.66, "latest_week": "2026-07-17", "one_week_move": -3.5, "four_week_move": -12.2, "twelve_week_move": -2.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.231774, "market_dynamics_buy_signal": false, "relative_strength": -23.09596, "fair_value_gap": -1.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.6978, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.5% over one week, -12.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Market source", "count": 8}, {"label": "marketscreener.com", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "Quartr", "count": 4}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 20}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.5% over one week, -12.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Here's Why You Should Add INKT Stock to Your Portfolio Now"}], "updated_at": "2026-07-23T10:29:48.101743+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}